U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07095075) titled 'A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases' on June 23.
Brief Summary: This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed/refractory autoimmune diseases.
Study Start Date: Aug. 22
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Autoimmune Diseases
Intervention:
BIOLOGICAL: LUCAR-DKS1 NK cells
Prior to the infusion of the LUCAR-DKS1 cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
Recruitment Status: NOT_YET_RECRUITING
...